While GLP-1s have, for years, been a prescribed treatment for type 2 diabetes, they now are an FDA-approved weight-loss drug that also reduce the risk of certain cancers, heart disease, cognitive decline and more
The most commonly reported side effects include nausea, vomiting, diarrhoea, constipation and abdominal discomfort
Instead, treatment follows a maintenance phase approach where your dose may gradually increase over 4 to 8 weeks to reach your therapeutic target
Related Content KRAS G12D inhibitors continue to advance, but treatment resistance remains an important challenge
A French database study initially suggested increased thyroid cancer risk with GLP-1 medications
Hyperhomocysteinemia can also occur if you have mutations in genes involved with homocysteine metabolism